New Enterprise Associates

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.

Nodar, Inc. specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. The company offers innovative LiDAR technology and a 3D stereo vision system called Nodar Longbow, which is designed to enhance the capabilities of autonomous vehicles. Founded in 2018 and based in Boston, Massachusetts, Nodar aims to provide a cost-effective and high-performance solution for the automotive, marine, and railway industries. Their products, including the Hammerhead system, utilize off-the-shelf cameras to deliver precise depth sensing, targeting applications for level 3 and level 4 autonomous vehicles. This technology supports functions such as collision warning, path planning, and automatic emergency braking, contributing to improved safety and performance in the automotive sector.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Neo Cybernetica specializes in the development of cybernetics technology aimed at enhancing the capabilities of artificial intelligence systems. By leveraging advanced communication and automatic control systems, the company focuses on creating AI systems that can operate independently as well as collaborate effectively with humans. This innovative approach positions Neo Cybernetica to address future opportunities and challenges, ultimately contributing to the advancement of AI technologies that can benefit society in the coming decades.

HOS is an AI technology company that develops scalable technologies to achieve significant and constructive changes in the world.

Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Candy is a multifaceted company that operates in the digital collectible and confectionery sectors. It develops sports and culture digital assets, providing authentic digital experiences that engage fans and connect them with their interests. Additionally, Candy.com serves as an online retailer catering to the growing demand for bulk, gourmet, and gift confectionery products, offering competitive pricing, expedited shipping, and a unique shopping experience. Furthermore, Candy Digital specializes in non-fungible tokens (NFTs), enabling fans to buy and trade officially licensed tokens related to Major League Baseball. Launched in 2021, this segment of the business was established by notable figures in the industry and reflects Candy's commitment to integrating technology with fan engagement.

Neural Magic is unlocking the possibility of machine learning, by re-imagining how deep learning is done. A team of pioneers, we believe machine learning has the potential to alter the trajectory of human history. Break free of limitations. Be a part of the future.

Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.

Berkshire Grey, Inc. specializes in developing artificial intelligence-driven robotic and automated material handling systems aimed at enhancing omnichannel fulfillment. Founded in 2013 and based in Lexington, Massachusetts, the company offers a range of solutions, including AI software, robotic arms, mobile robotic systems, and advanced sorting technologies. Its systems leverage artificial intelligence, computer vision, and machine learning to automate tasks traditionally performed by humans, thereby increasing accuracy and throughput in logistics and supply chain operations. Berkshire Grey's technology is designed to handle diverse products and packaging types, providing a significant competitive advantage to its customers. The company primarily generates its revenue from North America and operates as a subsidiary of SoftBank Group Corp.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Plaid Inc. is a technology platform that enables users to connect their bank accounts to various financial applications, facilitating a more modern and digitally-enabled financial system. Founded in 2012 and headquartered in San Francisco, the company offers a suite of APIs that allows developers to create innovative financial products. Its offerings include tools for accessing transaction histories, authenticating bank accounts, verifying user identities, confirming real-time account balances, and assessing borrowers' assets and income. Plaid's solutions cater to a wide range of financial activities, including personal finances, consumer payments, lending, and business transactions. The platform serves a diverse clientele, including Fortune 50 companies, and aims to democratize financial services by providing the necessary infrastructure for both small startups and large financial institutions to enhance their service offerings.

Burrow, Inc. is a furniture design and manufacturing company based in New York, founded in 2016. It specializes in creating luxury furniture for homes, offering a diverse range of products including sofas, sectionals, sleepers, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories like pillows and throws. The furniture is handcrafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow sells its products through physical showrooms located in several states, including Washington, Massachusetts, Texas, and California, as well as online. The company also operates a manufacturing facility in Mexico City, Mexico.

New Wave Foods, Inc. specializes in producing and selling plant-based seafood products, focusing primarily on sustainable shrimp alternatives. Founded in 2015 and headquartered in San Francisco, California, the company offers a variety of items, including sautéed, grilled, breaded, and fried shrimp, as well as shrimp tacos and salads. Its products are made from sustainably sourced seaweed and soy protein, enriched with natural flavors and essential amino acids, providing a healthy, low-calorie, and zero-cholesterol option for consumers. Targeting the culinary market in the United States, New Wave Foods aims to preserve and enrich seafood traditions through its innovative plant-based offerings.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.

Berkshire Grey, Inc. specializes in developing artificial intelligence-driven robotic and automated material handling systems aimed at enhancing omnichannel fulfillment. Founded in 2013 and based in Lexington, Massachusetts, the company offers a range of solutions, including AI software, robotic arms, mobile robotic systems, and advanced sorting technologies. Its systems leverage artificial intelligence, computer vision, and machine learning to automate tasks traditionally performed by humans, thereby increasing accuracy and throughput in logistics and supply chain operations. Berkshire Grey's technology is designed to handle diverse products and packaging types, providing a significant competitive advantage to its customers. The company primarily generates its revenue from North America and operates as a subsidiary of SoftBank Group Corp.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Neural Magic is unlocking the possibility of machine learning, by re-imagining how deep learning is done. A team of pioneers, we believe machine learning has the potential to alter the trajectory of human history. Break free of limitations. Be a part of the future.

Neural Magic is unlocking the possibility of machine learning, by re-imagining how deep learning is done. A team of pioneers, we believe machine learning has the potential to alter the trajectory of human history. Break free of limitations. Be a part of the future.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Burrow, Inc. is a furniture design and manufacturing company based in New York, founded in 2016. It specializes in creating luxury furniture for homes, offering a diverse range of products including sofas, sectionals, sleepers, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories like pillows and throws. The furniture is handcrafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow sells its products through physical showrooms located in several states, including Washington, Massachusetts, Texas, and California, as well as online. The company also operates a manufacturing facility in Mexico City, Mexico.

Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.

Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Plaid Inc. is a technology platform that enables users to connect their bank accounts to various financial applications, facilitating a more modern and digitally-enabled financial system. Founded in 2012 and headquartered in San Francisco, the company offers a suite of APIs that allows developers to create innovative financial products. Its offerings include tools for accessing transaction histories, authenticating bank accounts, verifying user identities, confirming real-time account balances, and assessing borrowers' assets and income. Plaid's solutions cater to a wide range of financial activities, including personal finances, consumer payments, lending, and business transactions. The platform serves a diverse clientele, including Fortune 50 companies, and aims to democratize financial services by providing the necessary infrastructure for both small startups and large financial institutions to enhance their service offerings.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Formlabs Inc. specializes in designing and manufacturing 3D printing systems aimed at professionals in various fields, including engineering, design, education, healthcare, and jewelry. Founded in 2011 and headquartered in Somerville, Massachusetts, the company has expanded its presence internationally with offices in Germany, Japan, China, Singapore, Hungary, and North Carolina. Formlabs' product lineup features advanced 3D printers, such as the Form 3, Form 3B, and Fuse 1, which utilize Low Force Stereolithography (LFS) technology to deliver high-resolution prints. Additionally, the company provides a range of materials, including standard, castable, flexible, tough, and dental SG options, along with software tools like PreForm for model preparation. Formlabs is recognized for its commitment to innovation, offering post-processing solutions and manufacturing systems that cater to the needs of engineers, designers, and makers worldwide.

Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise. Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively. Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Burrow, Inc. is a furniture design and manufacturing company based in New York, founded in 2016. It specializes in creating luxury furniture for homes, offering a diverse range of products including sofas, sectionals, sleepers, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories like pillows and throws. The furniture is handcrafted from sustainably-sourced hardwood and features non-toxic, scratch- and stain-resistant fabrics. Burrow sells its products through physical showrooms located in several states, including Washington, Massachusetts, Texas, and California, as well as online. The company also operates a manufacturing facility in Mexico City, Mexico.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company dedicated to developing novel, non-opioid, and non-addictive therapies for chronic pain management. Founded in 2013 and based in Boston, Massachusetts, the company’s product pipeline includes CNTX-4975, currently undergoing Phase III trials for knee osteoarthritis pain and Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials for various chronic pain conditions, while CNTX-6970 targets inflammatory pain and CNTX-2022, a high-concentration topical gel formulation of lidocaine, is also in Phase I trials for superficial musculoskeletal pain and related conditions. Furthermore, CNTX-6016 is a pre-clinical candidate aimed at treating chronic neuropathic pain. Centrexion Therapeutics is committed to addressing the unmet medical needs in chronic pain treatment by focusing on safety and efficacy.

We offer a fully collaborative, modern digital experience for learning and communication. The Retrieve platform can be used by both education and enterprise clients. Teach and maintain courses, conduct student assessments. Communicate live or asynchronously via web conferences, discussion boards, and chat to students or remote employees. Share notes, files or images, distribute technical manuals, user guides and other documentation.

Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.

Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.

Tulip Interfaces, Inc. is a company that specializes in developing applications for the manufacturing sector. Founded in 2012 and based in Somerville, Massachusetts, Tulip offers a Manufacturing App Platform that integrates data from various sources, including sensors, to create real-time digital work instructions and visualizations. This platform connects existing shop floor equipment with operator inputs, enhancing operational efficiency. Tulip's technology leverages advancements in intelligent hardware, computer vision, user interfaces, and machine learning, bridging the gap between traditional manufacturing IT systems and the dynamic needs of the shop floor. The company serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, with its solutions deployed across multiple global customers.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Intrinsic Therapeutics, Inc. develops and manufactures medical devices aimed at treating lumbar disc herniations, primarily under the trade name Barricaid. The company specializes in creating anular prostheses for partial replacement following discectomy surgery, as well as an anular closure device designed to prevent reherniations in patients with anular defects. Barricaid enables the reconstruction of weakened and ruptured spinal tissues, addressing issues related to sciatica and low back pain. Intrinsic Therapeutics serves both surgeons and patients and distributes its products across various countries, including Germany, Austria, Australia, and several others in Europe and Latin America. Founded in 2000 and based in Woburn, Massachusetts, the company also maintains offices in Oirschot, The Netherlands, and Düsseldorf, Germany.

Fam's mission is to build products that revolutionize the way teens and millennials communicate. They believe in a calculated combination of live group video and group chat messaging to execute this. It is the world’s first group video chat app for iMessage, with over 7 million users. Their app instantly connects with the family and friends closest to its user through group video calling, right from their iPhone, and Android text message app.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.

Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.

ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.

Barkly is an endpoint protection platform focused on safeguarding users from contemporary cyber threats. The platform employs a patented method that integrates responsive machine learning with runtime behavior analysis to effectively block various types of attacks such as file-based, fileless, and exploit breaches. Barkly's technology offers deep CPU-level visibility and operates without compromising system performance, ensuring comprehensive protection against a wide range of cyber threats, including exploits, scripts, executables, and ransomware. The platform is designed to deliver robust security while minimizing false positives and simplifying management for users.

Guideline, Inc. offers an automated technology solution for retirement plan administration and compliance, focusing primarily on 401(k) planning for growing businesses. Founded in 2015 and headquartered in San Mateo, California, with an additional office in Portland, Maine, the company provides a comprehensive platform that manages all aspects of retirement planning, including plan design, participant enrollment, education, recordkeeping, investment management, and compliance reporting. Unique in its approach, Guideline utilizes a straightforward pricing model based on a flat fee per participant, distinguishing itself from the traditional asset-based fee structures commonly found in the industry. The platform continuously integrates users' financial ecosystems, offering ongoing recommendations and adjustments to help optimize retirement savings potential.

Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.

Plaid Inc. is a technology platform that enables users to connect their bank accounts to various financial applications, facilitating a more modern and digitally-enabled financial system. Founded in 2012 and headquartered in San Francisco, the company offers a suite of APIs that allows developers to create innovative financial products. Its offerings include tools for accessing transaction histories, authenticating bank accounts, verifying user identities, confirming real-time account balances, and assessing borrowers' assets and income. Plaid's solutions cater to a wide range of financial activities, including personal finances, consumer payments, lending, and business transactions. The platform serves a diverse clientele, including Fortune 50 companies, and aims to democratize financial services by providing the necessary infrastructure for both small startups and large financial institutions to enhance their service offerings.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.

Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.

Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.

TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Docent Health's mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.

DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing innovative therapeutics for patients with rare genetic disorders of hemoglobin, particularly sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing IMR-687, a once-daily oral therapy designed to be a potent small molecule inhibitor of PDE9. This therapeutic aims to address the significant health challenges associated with these conditions, which can lead to reduced healthy red blood cells and various complications. Imara was established following a collaboration between Cydan Development and H. Lundbeck A/S, with initial funding from notable life science investors.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.

Sundar, Inc. operates a curated digital platform that facilitates material discovery and supplier sourcing for the apparel and design industries. Founded in 2013 and based in Boston, Massachusetts, the company connects creative professionals with quality materials and qualified vendors globally. By offering centralized digital catalogs, advanced search features, and data-driven recommendations, Sundar enhances the sourcing process for both emerging and established designers. The platform promotes collaboration between material research, design, and production teams, streamlining the discovery and sampling of textiles and raw materials. Recognized with awards from prestigious organizations and featured in notable publications, Sundar has established itself as a key player in modernizing the apparel supply chain, which has traditionally been antiquated and opaque. The company has received backing from top venture capital firms and has roots in respected incubators such as MIT and Techstars.

Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.

GLAMSQUAD, Inc., operating as GLAM Group, is a New York-based company that provides on-demand beauty services. Founded in 2013, it offers hair, makeup, and nail services in various cities including New York City, Los Angeles, Miami, Washington D.C., Boston, and the San Francisco Bay Area. GLAMSQUAD employs trained and vetted beauty professionals who deliver personalized services in clients' homes, at events, or in offices. The company utilizes a mobile app and website to facilitate easy booking, allowing clients to select services, dates, and locations. In addition to its service offerings, GLAMSQUAD has expanded into retail with a line of hair and makeup products, developed in response to customer feedback. The integration of technology helps match professionals with clients, ensuring a tailored experience.

Acquia Inc. is a provider of cloud-based solutions designed to build, deliver, and optimize digital experiences for various sectors, including government, education, consumer brands, and financial services. Founded in 2007 and headquartered in Boston, Massachusetts, Acquia offers a range of products, including Acquia Cloud, a Platform-as-a-Service for managing Drupal websites, and Acquia Lift, which facilitates the creation of brand and campaign sites. Other notable solutions include Acquia Content Hub for content distribution, Acquia Journey for customer journey mapping, and Acquia Digital Asset Manager for centralizing creative assets. The company's platform enables organizations to enhance customer engagement through cross-channel, contextually relevant digital experiences, supporting clients like the BBC, Nasdaq, and Stanford University in accelerating their time to market. Acquia also offers technical support and services, ensuring clients can effectively implement and maintain their digital strategies.

Onshape Inc., founded in 2012 and based in Cambridge, Massachusetts, is a developer of cloud-based 3D design software. The platform integrates computer-aided design (CAD) with data management, collaboration tools, and real-time analytics, enabling professional engineers to streamline their product development processes. Onshape's modern CAD system enhances productivity by providing secure, simultaneous access to a single master version of design data, which can be accessed from any device without data loss. The platform has been widely adopted by thousands of companies, facilitating the design of various products, including robotics and biomedical devices. In November 2019, Onshape was acquired by PTC Inc., further expanding its capabilities and market reach.

Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Guideline, Inc. offers an automated technology solution for retirement plan administration and compliance, focusing primarily on 401(k) planning for growing businesses. Founded in 2015 and headquartered in San Mateo, California, with an additional office in Portland, Maine, the company provides a comprehensive platform that manages all aspects of retirement planning, including plan design, participant enrollment, education, recordkeeping, investment management, and compliance reporting. Unique in its approach, Guideline utilizes a straightforward pricing model based on a flat fee per participant, distinguishing itself from the traditional asset-based fee structures commonly found in the industry. The platform continuously integrates users' financial ecosystems, offering ongoing recommendations and adjustments to help optimize retirement savings potential.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the complement system's excessive activation. Utilizing a proprietary peptide chemistry platform, the company creates synthetic macrocyclic peptides that possess the specificity of antibodies and the advantageous properties of small molecules. Its primary product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. Ra Pharmaceuticals is also exploring pre-clinical programs targeting various complement factors for conditions such as C3 glomerulonephritis and autoimmune diseases. Additionally, the company has a collaboration with Merck & Co. to identify orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Barkly is an endpoint protection platform focused on safeguarding users from contemporary cyber threats. The platform employs a patented method that integrates responsive machine learning with runtime behavior analysis to effectively block various types of attacks such as file-based, fileless, and exploit breaches. Barkly's technology offers deep CPU-level visibility and operates without compromising system performance, ensuring comprehensive protection against a wide range of cyber threats, including exploits, scripts, executables, and ransomware. The platform is designed to deliver robust security while minimizing false positives and simplifying management for users.

Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise. Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively. Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Founded in 2011 and based in Waltham, Massachusetts, the company works on innovative pharmaceutical preparations aimed at diagnosing and treating oncological and inflammatory conditions. Its drug development pipeline includes micro-environment activated therapeutics that utilize pleiotropic mechanisms to inhibit the synthesis and stabilization of extracellular matrix and to silence activated stromal cells. Through these novel approaches, XTuit Pharmaceuticals seeks to improve cancer therapies by addressing the tumor microenvironment effectively.

Lattice Engines, Inc. is a software company that develops SaaS-based predictive applications tailored for marketing and sales organizations. Founded in 2006 and headquartered in San Mateo, California, Lattice provides a suite of solutions designed to enhance sales and marketing effectiveness. Key offerings include Lattice Atlas, which integrates multiple data sources to build targeted audiences using artificial intelligence, and Lattice for Salesforce, which delivers sales analytics. The company also offers predictive insights for marketing programs through Lattice for Marketo, as well as tools for lead scoring, customer retention, and targeted selling strategies. These applications leverage advanced machine learning to analyze buying signals and improve marketing performance. Lattice has established a strategic partnership with Engagio Inc. and operates additional offices in Austin, Boston, and New York. As of July 2019, it functions as a subsidiary of The Dun & Bradstreet Corporation.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Interleukin Genetics, Inc. is a company that specializes in personalized health through genetic testing. It develops and sells genetic tests aimed at helping individuals improve their health and wellness. The company focuses on two main areas: providing genetic test products directly to consumers and through sales partners, and conducting research and development to create genetic tests in collaboration with partners for medical and dental applications. By offering personalized insights related to chronic diseases and health conditions, Interleukin Genetics aims to empower individuals with the information needed to make informed decisions about their health, including specific dietary and exercise recommendations. This approach aligns with their mission of enhancing preventive health measures and improving overall health outcomes.

Plaid Inc. is a technology platform that enables users to connect their bank accounts to various financial applications, facilitating a more modern and digitally-enabled financial system. Founded in 2012 and headquartered in San Francisco, the company offers a suite of APIs that allows developers to create innovative financial products. Its offerings include tools for accessing transaction histories, authenticating bank accounts, verifying user identities, confirming real-time account balances, and assessing borrowers' assets and income. Plaid's solutions cater to a wide range of financial activities, including personal finances, consumer payments, lending, and business transactions. The platform serves a diverse clientele, including Fortune 50 companies, and aims to democratize financial services by providing the necessary infrastructure for both small startups and large financial institutions to enhance their service offerings.

ClearMotion, Inc., an automotive technology company, develops a suspension system that makes automotive systems that use a combination of hardware and software to anticipate, absorb, and counteract shocks and vibrations that cars pick up from the road. It specializes in suspension technology, road surface mapping, and active seating motion control aspects. ClearMotion, Inc. was formerly known as Levant Power Corporation and changed its name to ClearMotion, Inc. in January 2017. The company was incorporated in 2008 and is based in Billerica, Massachusetts with an operation in Nuneaton, United Kingdom.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

DataRobot, Inc. develops an automated machine learning platform designed to help enterprises build predictive models efficiently. The company's offerings include DataRobot Cloud, a predictive analytics platform available on-site or via the cloud, and DataRobot MLOps, which focuses on the deployment, monitoring, and management of machine learning models within organizations. Additionally, DataRobot Enterprise provides features such as flexible deployment, governance, and support, along with packages aimed at accelerating artificial intelligence projects and education services. The platform is suitable for a diverse range of professionals, including business analysts, data scientists, and IT specialists across various industries like banking, healthcare, and marketing. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot also maintains operations in several international locations, including London, Paris, Kyiv, Tokyo, and Singapore. The company has established strategic partnerships to enhance its offerings in the competitive AI landscape.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.